Letermovir

Phase 3Recruiting

1 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cytomegalovirus Infections

Conditions

Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant

Trial Timeline

Aug 8, 2024 → Sep 1, 2026

NCT ID

NCT06407232

About Letermovir

Letermovir is a phase 3 stage product being developed by Merck for Cytomegalovirus Infections. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06407232. Target conditions include Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant.

What happened to similar drugs?

8 of 20 similar drugs in Cytomegalovirus Infections were approved

Approved (8) Terminated (2) Active (10)

✅LetermovirMerckApproved

✅Single arm (ganciclovir and valganciclovir)RocheApproved

✅Ganciclovir + valganciclovir [Valcyte]RocheApproved

✅ValganciclovirRocheApproved

✅valganciclovir [Valcyte]RocheApproved

✅Valganciclovir + CMV hyperimmune globulin + ValganciclovirCSLApproved

✅CytogamKamadaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07199465	Phase 1	Recruiting	Apr 24, 2026	May 19, 2028	Cytomegalovirus Prophylaxis
NCT06407232	Phase 3	Recruiting	Aug 8, 2024	Sep 1, 2026	Cytomegalovirus Infections
NCT05789615	Pre-clinical	Completed	Apr 1, 2023	Jan 10, 2025	CMV Infection
NCT05763823	Phase 3	Completed	Mar 24, 2023	Apr 18, 2024	Cytomegalovirus Infection
NCT04904614	Approved	Completed	Jan 5, 2022	Jan 14, 2025	Cytomegalovirus Disease
NCT04312841	Phase 2	Completed	Sep 15, 2020	Apr 9, 2024	B-Cell Prolymphocytic Leukemia
NCT03728426	Phase 2	Completed	Jan 11, 2019	Mar 28, 2022	Cytomegalovirus Infections

Competing Products

20 competing products in Cytomegalovirus Infections

See all competitors

Product	Company	Stage	Hype Score
mRNA-1273	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 3	0
ASP0113 + Placebo	Astellas Pharma	Phase 2	35
ASP0113 + Placebo	Astellas Pharma	Phase 3	40
Letermovir oral granules + Letermovir tablet + Letermovir intravenous	Merck	Phase 2	35
Letermovir 240 mg Oral Tablet	Merck	Phase 2	42
Letermovir tablet + Letermovir IV	Merck	Phase 3	40
Letermovir	Merck	Phase 1	36
Letermovir	Merck	Approved	43
Letermovir 480 MG [Prevymis]	Merck	Phase 2	42
V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose ID	Merck	Phase 1	29
Ganciclovir	Merck	Pre-clinical	26
Letermovir + Placebo	Merck	Phase 3	40